Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sascha Pahernik

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Oncotarget|June 2, 2018
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing diseaseStefanie Zschäbitz, Florian A Distler, Benjamin Krieger, et al.
The Journal of Pathology|July 17, 2015
PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomasStephan Macher-Goeppinger, Martina Keith, Katrin E Tagscherer, et al.
Oncotarget|November 2, 2017
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapySteffen Dietz, Holger Sültmann, YueJun Du, et al.
World Journal of Urology|June 27, 2018
Ablation energies for focal treatment of prostate cancerOlivia Lodeizen, Martijn de Bruin, Scott Eggener, et al.
Annals of Surgical Oncology|August 2, 2012
Multimedia support for improving preoperative patient education: a randomized controlled trial using the example of radical prostatectomyJohannes Huber, Andreas Ihrig, Mohammed Yass, et al.
Oncotarget|February 5, 2019
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostateLeonidas Apostolidis, Cathleen Nientiedt, Eva Caroline Winkler, et al.
Diagnostics (Basel, Switzerland)|January 28, 2026
Diagnostic Performance and Clinical Utility of the Uromonitor<sup>®</sup> Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-AnalysisJulio Ruben Rodas Garzaro, Anton Kravchuk, Maximilian Burger, et al.
The Journal of Urology|April 24, 2013
Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancerTimur H Kuru, Matthias C Roethke, Jonas Seidenader, et al.
BJU International|November 24, 2019
External validation of novel magnetic resonance imaging-based models for prostate cancer predictionLukas Püllen, Jan P Radtke, Manuel Wiesenfarth, et al.
Urology|February 5, 2013
Pediatric case report on magnetic resonance imaging/transrectal ultrasound-fusion biopsy of rhabdomyosarcoma of the bladder/prostate: a new tool to reduce therapy-associated morbidity?Timur H Kuru, Matthias C Roethke, Joanne Nyarangi-Dix, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Oncotarget|June 2, 2018
Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing diseaseStefanie Zschäbitz, Florian A Distler, Benjamin Krieger, et al.
The Journal of Pathology|July 17, 2015
PBRM1 (BAF180) protein is functionally regulated by p53-induced protein degradation in renal cell carcinomasStephan Macher-Goeppinger, Martina Keith, Katrin E Tagscherer, et al.
Oncotarget|November 2, 2017
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapySteffen Dietz, Holger Sültmann, YueJun Du, et al.
World Journal of Urology|June 27, 2018
Ablation energies for focal treatment of prostate cancerOlivia Lodeizen, Martijn de Bruin, Scott Eggener, et al.
Annals of Surgical Oncology|August 2, 2012
Multimedia support for improving preoperative patient education: a randomized controlled trial using the example of radical prostatectomyJohannes Huber, Andreas Ihrig, Mohammed Yass, et al.
Oncotarget|February 5, 2019
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostateLeonidas Apostolidis, Cathleen Nientiedt, Eva Caroline Winkler, et al.
Diagnostics (Basel, Switzerland)|January 28, 2026
Diagnostic Performance and Clinical Utility of the Uromonitor<sup>®</sup> Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-AnalysisJulio Ruben Rodas Garzaro, Anton Kravchuk, Maximilian Burger, et al.
The Journal of Urology|April 24, 2013
Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancerTimur H Kuru, Matthias C Roethke, Jonas Seidenader, et al.
BJU International|November 24, 2019
External validation of novel magnetic resonance imaging-based models for prostate cancer predictionLukas Püllen, Jan P Radtke, Manuel Wiesenfarth, et al.
Urology|February 5, 2013
Pediatric case report on magnetic resonance imaging/transrectal ultrasound-fusion biopsy of rhabdomyosarcoma of the bladder/prostate: a new tool to reduce therapy-associated morbidity?Timur H Kuru, Matthias C Roethke, Joanne Nyarangi-Dix, et al.
Pageof 13